Harrow Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $64.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen has given his Buy rating due to a combination of factors that highlight Harrow Health’s promising growth trajectory. The company aims to significantly increase its quarterly revenue to $250 million by the end of 2027, driven by strategic initiatives such as the VEVYE Access for All (VAFA) program, which has already shown success in boosting new prescription growth. Harrow Health’s management is focused on expanding its ophthalmic product offerings, including the anticipated launch of new products and the implementation of the Harrow Access for All (HAFA) program, which is expected to enhance patient access and affordability.
Yi Chen’s rating is also supported by Harrow Health’s demonstrated growth since 2020 and its strategic plan to continue this momentum through product launches and acquisitions. The HAFA program, set to launch in late 2025, aims to streamline access to Harrow’s medications, potentially increasing prescription volume and profitability despite a possible reduction in average selling prices. Overall, Yi Chen sees these strategic initiatives as key drivers for Harrow Health’s future success, justifying the Buy rating and a price target of $64.
In another report released today, BTIG also maintained a Buy rating on the stock with a $63.00 price target.